ChickenStockChickenStock

AI English summary of an SEC filing — figures as filed

Quest Diagnostics logoQuest Diagnostics DGX

Quest Diagnostics said net revenues for the quarter ended March 31, 2025 increased 12.1% compared to the prior year period, with DIS revenues up 12.7%. The company said recent acquisitions contributed approximately 10.0% to DIS revenues.

10-QQuarterly reportFiled Period of report Summary published (UTC)

Key points

AI summary
  1. Quest Diagnostics said net revenues for the quarter ended March 31, 2025 increased 12.1% compared to the prior year period, with DIS revenues up 12.7%. The company said recent acquisitions contributed approximately 10.0% to DIS revenues.

  2. Quest Diagnostics said DIS volume increased 12.4% compared to the prior year period, with recent acquisitions contributing approximately 13.3% and organic volume down 0.9%. Revenue per requisition increased 0.3%, and on an organic basis increased 3.6%, the company said.

  3. Quest Diagnostics said net cash provided by operating activities for Q1 2025 was $314 million, an increase of $160 million compared to $154 million in the prior year period. The company said it repaid in full the outstanding indebtedness under $600 million of 3.50% senior notes using a combination of cash on hand and $215 million of borrowings under its secured receivables credit facility.

  4. Quest Diagnostics said results for Q1 2025 were affected by certain items that on a net basis decreased diluted earnings per share by $0.27. These included pre-tax amortization expense of $39 million, or $0.26 per diluted share, and pre-tax charges of $19 million, or $0.13 per diluted share, primarily associated with workforce reductions and integration costs.

Key figures

Quarter ended March 31, 2025

Revenue
$2.7B
Operating income
$346M
Net income
$220M
EPS
$1.94
Operating cash flow
$314M

From the XBRL financial data filed with the SEC · not processed by AI.

Summary

AI-written

Analysis scope · Management's discussion (MD&A)We analyzed the Management's Discussion and Analysis (MD&A) section. Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

Q1 2025 Revenue Growth and Acquisition Contribution

Quest Diagnostics said net revenues for the quarter ended March 31, 2025 increased 12.1% compared to the prior year period, with DIS revenues up 12.7%. The company said recent acquisitions contributed approximately 10.0% to DIS revenues.

Source · Based on the MD&A text of the filing

DIS Volume Up 12.4%, Organic Volume Down 0.9%

Quest Diagnostics said DIS volume increased 12.4% compared to the prior year period, with recent acquisitions contributing approximately 13.3% and organic volume down 0.9%. Revenue per requisition increased 0.3%, and on an organic basis increased 3.6%, the company said.

Source · Based on the MD&A text of the filing

Q1 Operating Cash Flow and 3.50% Senior Notes Repayment

Quest Diagnostics said net cash provided by operating activities for Q1 2025 was $314 million, an increase of $160 million compared to $154 million in the prior year period. The company said it repaid in full the outstanding indebtedness under $600 million of 3.50% senior notes using a combination of cash on hand and $215 million of borrowings under its secured receivables credit facility.

Source · Based on the MD&A text of the filing

Q1 2025 Special Items' Impact on Earnings Per Share

Quest Diagnostics said results for Q1 2025 were affected by certain items that on a net basis decreased diluted earnings per share by $0.27. These included pre-tax amortization expense of $39 million, or $0.26 per diluted share, and pre-tax charges of $19 million, or $0.13 per diluted share, primarily associated with workforce reductions and integration costs.

Source · Based on the MD&A text of the filing

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

Source: SEC EDGAR (U.S. Securities and Exchange Commission). Item captions are the SEC's. The summary is for reference only and is not investment advice.